Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $21 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts BHVN Hot Sheet
Price: $14.45 --0%
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 4 | New: 9
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 4 | New: 9
Join SI Premium – FREE
Piper Sandler analyst Christopher J. Raymond lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $21.00 (from $23.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Biohaven Pharma (BHVN) PT Raised to $48 at Baird
- Citi Downgrades Randoncorp SA (RAPT4:BZ) to Neutral
- Kingspan Group PLC (KSP:ID) PT Raised to EUR109 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT Change, Hot CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
